A prospective, post-marketing study to evaluate the efficacy and safety of orlistat + resveratrol combination (Zytrim-R)

Zydus Lifesciences Ltd0 个研究点目标入组 264 人开始时间: 2022年7月4日最近更新: 2022年9月12日

适应症

试验速览

暂无简介。

•1. Subjects of either sex (male or female) having age =18 years
•2. Subjects with a BMI =25 kg/m² (overweight or obese) with or without metabolic syndrome (or components of metabolic syndrome like hypertension, type 2 diabetes, dyslipidemia or fatty liver) and prescribed orlistat or orlistat+resveratrol by their treating physician
•3. Subjects and/or their legal guardian able to provide written informed consent and willing to comply with physician’s instructions

•1. Subjects receiving orlistat other than Zytrim or Zytrim-R
•2. Any contraindication for orlistat or orlistat + resveratrol as per the prescribing information
•3. Subject simultaneously participating in any other clinical studies or having participated in any other clinical trial in the past 3 months (except survey-based studies)
•4. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, HIV infection, or coronary artery disease)

发起方

Zydus Lifesciences Ltd